Drugs / TRD205
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07121023 | Aug → Dec 2025 overdue | — | Beijing Tide Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07123428 | Jan → Nov 2024 | — | Beijing Tide Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07543796 | Mar → Jun 2026 overdue | — | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07121101 | Sep → Nov 2025 overdue | — | Beijing Tide Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07123402 | Apr 2025 → Apr 2026 overdue | neuralgia | Beijing Tide Pharmaceutical Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRD205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07121023 ↗ |
| Route | Oral | “Administered orally every 12 hours” NCT07121023 ↗ |